Compounds > 4-amino-2-nitrotoluene
Page last updated: 2024-12-05

4-amino-2-nitrotoluene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-amino-2-nitrotoluene: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8390
CHEMBL ID1350617
CHEBI ID81670
SCHEMBL ID100616
SCHEMBL ID17347354
MeSH IDM0093596

Synonyms (73)

Synonym
AC-1739
benzenamine, 4-methyl-3-nitro-
4-methyl-3-nitroaniline
2-nitro-4-aminotoluene
3-nitro-p-toluidine
m-nitro-p-toluidine
3-nitro-4-methylaniline
p-toluidine, 3-nitro-
119-32-4
nsc7731
nsc-7731
4-amino-2-nitrotoluene
5-nitro-4-toluidine
3-nitro-4-toluidin
wln: zr d1 cnw
AC-907/25014173
4am2nt
NCGC00091307-01
inchi=1/c7h8n2o2/c1-5-2-3-6(8)4-7(5)9(10)11/h2-4h,8h2,1h
LS-614 ,
gl-amin [czech]
nsc 7731
brn 0638984
einecs 204-314-0
ccris 3003
3-nitro-4-toluidin [czech]
4-methyl-3-nitroaniline, 97%
M-4200
STK387113
C18320
4-amino-1-methyl-2-nitrobenzene
N0278
AKOS000119120
A804255
4-methyl-3-nitro-aniline
NCGC00091307-02
4-methyl-3-nitro aniline
(4-methyl-3-nitro-phenyl)-amine
NCGC00257657-01
dtxcid805633
cas-119-32-4
dtxsid7025633 ,
tox21_200103
4-methyl-3-nitrobenzenamine
sm8uz1q81f ,
gl-amin
4-12-00-01997 (beilstein handbook reference)
unii-sm8uz1q81f
4-methyl-3-nitrophenylamine
BP-20389
FT-0619031
PS-5957
AM20060491
AB00514384-03
SCHEMBL100616
CHEBI:81670 ,
SCHEMBL17347354
(4-methyl-3-nitrophenyl)amine
4-methyl-3-nitro-phenylamine
3-nitro-4-methyl-aniline
CHEMBL1350617
1-amino-3-nitro-4-methylbenzene
4-methyl-3-nitroaniline;
mfcd00007910
F8880-0867
4-methyl-3-nitroaniline, analytical standard
Q27155550
BCP32906
3-nitro-p-toluidine;3-nitro-4-methylaniline;4-amino-2-nitrotoluene
NCGC00091307-03
3-nitro-4-methylanilin
EN300-19073
Z104472590

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" A no-observed adverse effect level could not be determined."( Toxicity assessment of 4-amino-2-nitrotoluene.
Houpt, JT; Johnson, MS; Leach, GJ; Reddy, G; Williams, LR, )		0.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency3.98110.125919.1169125.8920AID2549
GLI family zinc finger 3Homo sapiens (human)Potency0.08700.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency30.85610.000221.22318,912.5098AID1259243
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.58930.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency56.49640.001022.650876.6163AID1224838; AID1224893
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency61.56600.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency10.94820.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency17.78280.000229.305416,493.5996AID588514
aryl hydrocarbon receptorHomo sapiens (human)Potency58.99090.000723.06741,258.9301AID743085; AID743122
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (3)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.62 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2,4-diaminotoluene
2,4-diaminotoluene: RN given refers to unlabeled parent cpd; structure. 2,4-diaminotoluene : An aminotoluene that is para-toluidine with an additional amino group at position 2.		2.7330aminotoluenemetabolite
2,4-dinitrotoluene
2,4-dinitrotoluene : A dinitrotoluene in which the methyl group is ortho to one of the nitro groups and para to the other. It is the most common isomer of dinitrotoluene.		2.7330dinitrotoluene
dinitrobenzenes
Dinitrobenzenes: Benzene derivatives which are substituted with two nitro groups in the ortho, meta or para positions.		2.7330
ConditionIndicatedRelationship StrengthStudiesTrials